Mao J, Price D D, Lu J, Keniston L, Mayer D J
MGH Pain Center Department of Anesthesia and Critical Care, Massachusetts General Hospital, Harvard Medical School, Boston 02114, USA.
Neurosci Lett. 2000 Feb 11;280(1):13-6. doi: 10.1016/s0304-3940(99)00998-2.
A common obstacle in clinical management of pathological pain is the poor response to opioid analgesics. We now report that delta9-tetrahydrocannabinol (delta9-THC)-induced antinociception remained effective in rats with pathological pain. The selective central cannabinoid receptor antagonist SR141716A, but not the generic opioid receptor antagonist naloxone, blocked the delta9-THC antinociception. Moreover, there is no cross-tolerance between the antinociceptive effects of morphine and delta9-THC in pathological pain states. The results indicate that delta9-THC antinociception is both effective and independent of opioid receptors in rats with pathological pain. Thus, the cannabinoid analgesic system may be superior to opioids in alleviating intractable pathological pain syndromes.
病理性疼痛临床治疗中的一个常见障碍是对阿片类镇痛药反应不佳。我们现在报告，δ9-四氢大麻酚（δ9-THC）诱导的镇痛作用在患有病理性疼痛的大鼠中仍然有效。选择性中枢大麻素受体拮抗剂SR141716A而非通用阿片受体拮抗剂纳洛酮可阻断δ9-THC的镇痛作用。此外，在病理性疼痛状态下，吗啡和δ9-THC的镇痛作用之间不存在交叉耐受性。结果表明，在患有病理性疼痛的大鼠中，δ9-THC的镇痛作用既有效且独立于阿片受体。因此，大麻素镇痛系统在缓解顽固性病理性疼痛综合征方面可能优于阿片类药物。
